Yellow Fever Vaccine Singapore.
Yellow Fever Vaccine Singapore: Live attenuated yellow fever virus vaccine jab/shot/injection schedule, to vaccinate against the Yellow fever virus, to immunise against Yellow fever clinic, Singapore. Private and confidential service. Definitions, references, and latest news.
The 17D vaccine, which is based on a live, attenuated viral strain, is the only commercially available yellow fever vaccine. It is given as a single subcutaneous (or intramuscular) injection. Yellow fever vaccine is highly effective (approaching 100%). All individuals aged 9 months or older and living in countries or areas at risk should receive yellow fever vaccine.
Precautions and contraindications
With the exception of very rare cases of vaccine-associated neurotropic and viscerotropic disease (see below), the 17D vaccine is generally considered to be safe. However, some vaccine recipients develop mild systemic reactions, including myalgia and headache. Contraindications include true allergy to egg protein, immunodeficiency (congenital or acquired) and symptomatic HIV infection (Chapter 9). There is a theoretical risk of harm to the fetus if the vaccine is given during pregnancy and vaccination of nursing mothers should be avoided because of the risk for the transmission of 17D virus to and encephalitis in the breast-fed infant.These risks must be weighed against the risk to the mother of remaining unvaccinated and travelling to an area where exposure to YFV may occur. In general, unvaccinated pregnant or nursing women should be advised not to travel to such areas.
Hypersensitivity reactions are rare, particularly anaphylactic reactions. However, the vaccine is produced in embryonated chicken eggs and is contraindicated in persons with a history of oral egg intolerance or strong allergic reactions to egg-based products.
Encephalitis has been reported as a rare event following vaccination, principally in infants under 6 months of age. As a result, the vaccine is contraindicated in infants under 6 months of age and is not recommended for those aged 6–8 months, except during epidemics when the risk of YFV transmission may be very high.
Vaccine-associated viscerotropic disease is a recently described adverse event that on very rare occasions has occurred after the first immunization with the yellow fever 17D vaccine. Onset is within 10 days of vaccination and the pathological process is characterized by severe multi-organ failure and an overall case—fatality rate in excess of 60%. Known risk factors include a history of thymus disease (e.g. thymoma or thymectomy) and age ≥ 60 years. In the United Sates, the risk for people aged ≥ 70 years of contracting viscerotropic disease after receiving vaccination against yellow fever is estimated to be 2.4 cases/100 000 vaccine doses.
Increased incidence of vaccine-associated neurotropic disease (e.g. meningoencephalitis, acute disseminated encephalomyelitis and Guillain-Barré syndrome) has been reported in infants under 6 months of age and in vaccine recipients aged ≥60 years . The reported rate of vaccine-associated neurotropic disease in travellers from the United States and Europe ranges between 0.13 and 0.8 per 100 000 doses.
Yellow fever vaccination is required for travellers to certain countries and recommended for all travellers to countries or areas with risk of yellow fever transmission (see Country list and Annex 1). The risk to unvaccinated individuals who visit countries or areas where there may be yellow fever transmission is often greater than the risk of a vaccine-related adverse event. While yellow fever vaccination should be encouraged as a key prevention strategy, it is important to screen travel itineraries and carefully evaluate the potential risk of systemic illness after yellow fever vaccination. Great care should be exercised not to prescribe yellow fever vaccination to individuals who are not at risk of exposure to infection, based on an accurate assessment of the travel itinerary. Although vaccination is generally not recommended for travellers going to areas where the risk of exposure is low, any risk (e.g. as a result of prolonged travel or heavy exposure to mosquito bites) should be weighed against individual risk factors for vaccine-associated adverse events (e.g. altered immune status).
| Type of vaccine: Live, attenuated |
Number of doses: One dose of 0.5 ml
Booster: Currently every 10 years (if re-certification is needed)
Contraindications: Infants aged less than 6 months; history of allergy to egg or to any of the vaccine components, or hypersensitivity to a previous dose of the vaccine; thymoma or history of thymectomy, immunodeficiency from medication, disease or symptomatic HIV infection.
Adverse reactions: Rarely, neurological (encephalitis) or multi-organ failure resembling wild-type yellow fever
Before departure: International certificate of vaccination becomes valid 10 days after vaccination.
Recommended for: All travellers to countries and areas with risk of yellow fever transmission and when required by countries.
Special precautions: Not recommended for infants aged 6-8 months, except during epidemics when the risk of YF virus transmission may be very high. The risks and benefits of vaccination in this age group should be carefully considered before vaccination. The vaccine should be avoided during pregnancy or breastfeeding. However, pregnant or nursing women may be vaccinated during epidemics or if traveling to country or area a risk of transmission is unavoidable.
|Dose schedule||Price |
|Varilrix™|| Varicella zoster virus |
|Zostavax™||Herpes zoster Shingles||≥50y||1||$295/=|
|Stamaril®||Yellow fever virus||Yellow fever||9m-59y||1||10 yearly||$250/=|
|Inactivated / Whole / Viral & Bacterial|
|Rabipur®||Rabies virus||Rabies||any||3||d 0, 7, & 21 or 28||$call/=|
|Ixiaro®||Japanese encephalitis virus||Japanese encephalitis||≥17y||2||2nd: 28d after 1st||$386/=|
|1||Booster: 12-24m after 2nd|
|Dukoral®||Vibrio cholerae||Cholera||2-6y||3||1-6w interval||$113/=|
|1||Booster: 6m after 3rd|
|1||Booster: 2y after 2nd|
|Inactivated / Fractional / Protein|
|Intanza™||Influenza virus||Influenza||18-59y||1||1 yearly||$30/=|
|Fluarix™||Influenza virus||Influenza||6-36m||½||1 yearly||$30/=|
|Tetavax||Clostridium tetani||Tetanus||adults||3||1-2m interval |
3rd @ 6-12m
|Bordetella pertussis||Pertussis |
|Inactivated / Fractional / Polysaccharide / Pure|
|Typhim Vi®||Salmonella typhi||Typhoid fever||>5y||1||3 yearly||$48/=|
|Mencevax® ACWY||Neisseria meningitidis |
types A, C, W-135
|Inactivated / Fractional / Polysaccharide / Conjugate|
|Menactra®||Neisseria meningitidis |
types A, C, W-135
| Prevenar 13® (SG) / |
Prevnar 13® (US)
|Streptococcus pneumoniae |
types 1, 3, 4, 5,
6A, 6B, 7F, 9V, 14,
18C, 19A, 19F, 23F
|Pneumococcal infection||6w-6m||4||1m interval |
4th @ 12-15m
If the clinic attendance is just for vaccination alone, no additional consultation fees are charged.
Testing for immunity against the following is available:
|Varicella zoster virus||Varicella Zoster IgG Antibody||$44/=|
|Measles virus||Measles IgG Antibody||$90/=|
|Rubella virus||Rubella IgG Antibody||$24/=|
|Hepatitis A virus||Hepatitis A IgG Antibody||$30/=|
|Hepatitis B virus||Hepatitis B surface Antibody||$10/=|
Other vaccines not stocked
- Haemophilus influenzae type b Vaccine / HIB Vaccine
- Polio Vaccine
- Rotavirus Vaccine
- Tuberculosis Vaccine / TB Vaccine / BCG Vaccine
- Tick-Borne Encephalitis Vaccine / TBE Vaccine
- Live attenuated
- Hajj and Umrah Health Requirements
- Memish ZA. The Hajj: communicable and non-communicable health hazards and current guidance for pilgrims. Euro Surveill. 2010;15(39)
- Memish Z.A., Goubeaud A., Broker M., Malerczyk C., Shibl A.M. Invasive meningococcal disease and travel. J Infect Public Health. 2010;3(4):143-151.
|Dose schedule||Price |
|Havrix™ 1440 Adult||Hepatitis A virus||Hepatitis A||≥19y||2||m 0 & 6-12||$90/=|
|Twinrix®||Hepatitis A virus |
Hepatitis B virus
|Hepatitis A |
|1-15y||2||m 0, 6-12||$135/=|
|≥16y||3||m 0, 1, 6|
|4||d 0, 7, 21 & m 12|
|Inactivated / Fractional / Protein / Subunit / Recombinant|
|Engerix™-B 20 μg||Hepatitis B virus||Hepatitis B||11-15y||2||m 0, & 6||$50/=|
|≥20y||3||m 0, 1, & 6|
|4||m 0, 1, 2, & 12 or |
d 0, 7, 21 & m 12
types 6, 11, 16, & 18
| Genital warts |
|9-26y||3||m 0, 2, & 6 or |
m 0, 1, & 4
types 16, & 18
(31, 33, & 45)
|10-25y||3||m 0, 1, & 6 |
m 0, 1, & 5
m 0, 2½, 12
types 6, 11, 16, 18,
31, 33, 45,
52, & 58
|3||m 0, 2, & 6 or |
m 0, 1, & 4
For persons aged 0 to <18 years
|Vaccination against||Birth||1 month||3 months||4 months||5 months||6 months||12 months||15 months||18 months||6-7 years^||10-11 years^^|
|Hepatitis B||HepB (D1)||HepB (D2)||HepB (D3)#|
|Diphtheria, Tetanus, Pertussis||DTaP (D1)||DTaP (D2)||DTaP (D3)||DTaP (B1)||Tdap (B2)|
|Poliovirus||OPV (D1)||OPV (D2)||OPV (D3)||OPV (B1)||OPV (B2)||OPV (B3)|
|Measles, Mumps, Rubella||MMR (D1)||MMR (D2)##|
|Pneumococcal Disease||PCV (D1)||PCV (D2)||PCV (B1)|
|Human Papillomavirus||Recommended for females 9 to 26 years; three doses are required at intervals of 0, 2, 6 months|
|Influenza||Recommended annually for all children aged 6 months to <5 years and children aged 6 months to <18 years in high-risk groups|
- National Childhood and Adolescent Immunisation Schedule, Singapore For persons aged 0 to <18 years
- Infectious Diseases (Diphtheria and Measles Vaccination) Regulations